Incyte Genomics, Inc. News, Incyte Genomics, Inc. Quote, INCY Quote

Incyte Genomics, Inc. (NQ:INCY) Delayed: 21.41 +0.35 (1.66%)	Trade Now!
Previous Close	$21.06	52 Week High	$26.30
Open	$21.10	52 Week Low	$15.43
Day High	$21.52	P/E	N/A
Day Low	$20.72	EPS	$-0.11
Volume	747,524

Jun 16, 2013 02:00 AM Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
Jun 13, 2013 06:49 PM Form 4 INCYTE CORP For: Jun 11 Filed by: 14159, L.P.
Jun 13, 2013 06:00 AM Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Jun 12, 2013 05:15 PM Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information
Jun 11, 2013 01:14 PM UPDATE: Incyte (INCY) Drops; Morgan Stanley Notes Jakafi Had Withdrawal Syndrome
Jun 5, 2013 05:22 PM Form 8-K INCYTE CORP For: May 30
Jun 4, 2013 09:06 AM Incyte (INCY) Data Shows Long-Term Jakafi Use May Stabilize or Reverse Bone Marrow Fibrosis
Jun 4, 2013 09:00 AM Data Presented at 2013 ASCO Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients with
Jun 1, 2013 02:15 PM Incyte Presents Final Results from a Phase I Trial of INCB024360, a Novel Oral Immunotherapy, at ASCO
May 31, 2013 04:11 PM Form 4 INCYTE CORP For: May 30 Filed by: BAKER JULIAN

Jun 16, 2013 02:00 AM Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
Jun 13, 2013 06:00 AM Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Jun 12, 2013 05:15 PM Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information
Jun 4, 2013 09:00 AM Data Presented at 2013 ASCO Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients with
Jun 1, 2013 02:15 PM Incyte Presents Final Results from a Phase I Trial of INCB024360, a Novel Oral Immunotherapy, at ASCO
May 22, 2013 08:00 AM Incyte to Present at Upcoming Investor Conferences
May 10, 2013 03:20 PM SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and Upcoming Deadline -- INCY
May 3, 2013 08:00 AM Incyte to Present at Upcoming Investor Conferences
May 2, 2013 07:00 AM Incyte Reports First-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs
Apr 29, 2013 08:00 AM Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development

Jun 13, 2013 06:49 PM Form 4 INCYTE CORP For: Jun 11 Filed by: 14159, L.P.
Jun 5, 2013 05:22 PM Form 8-K INCYTE CORP For: May 30
May 31, 2013 04:11 PM Form 4 INCYTE CORP For: May 30 Filed by: BAKER JULIAN
May 31, 2013 04:11 PM Form 4 INCYTE CORP For: May 30 Filed by: BROOKE PAUL A
May 31, 2013 04:10 PM Form 4 INCYTE CORP For: May 30 Filed by: WHITFIELD ROY A
May 31, 2013 04:10 PM Form 4 INCYTE CORP For: May 30 Filed by: DE SCHUTTER RICHARD U
May 31, 2013 04:10 PM Form 4 INCYTE CORP For: May 30 Filed by: DIXON WENDY L
May 31, 2013 04:09 PM Form 4 INCYTE CORP For: May 30 Filed by: ARIKO BARRY A
May 28, 2013 05:06 PM Form 8-K INCYTE CORP For: May 24
May 21, 2013 04:35 PM Form 4 INCYTE CORP For: May 17 Filed by: WHITFIELD ROY A

Entities mentioned with INCY